Loss-of-function mutations in NaV1.7 cause congenital insensitivity to pain (CIP); this voltage-gated sodium channel is therefore a key target for analgesic drug development. The gene discussed is SCN9A; the disease is hereditary sensory and autonomic neuropathy.